Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2028.

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves ...

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...

Late-breaking results from the Phase 3 KEYNOTE-B15 trial were selected for the official Press Program and will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) ...